Mark Payton, Chief Executive Officer of Mercia, commented: “Axis Spine is a business we have been excited about for some time, actively supporting it from a start-up within our managed funds and, with the business reaching its next stage of maturity, we are pleased to make it our latest direct balance sheet investment.
“The innovative patented technology behind its lead device has significant benefits over incumbents, with differentiated FDA clearance now received, the team is well placed to move towards broader commercialization in the US. It’s a great example of the specialist sector and technological expertise that exists in the UK’s regions, and we look forward to supporting the team as they scale a unique product.”
Axis CEO Jon Arcos commented: “We are grateful for the support of existing investors and welcome new investor MedTex Ventures. Axis has a real opportunity to help surgeons create and maintain superior spinal alignment and in doing so, improve patient outcomes. This round of funding will allow us to scale up as well as complete and launch further innovative developments to advance spinal care”.
Axis Spine has received FDA clearance in the US and its first implant system is actively used in a limited number of locations. Axis Spine, which is based in St Albans, was founded by Jon Arcos, who has more than 25 years’ experience in the field of spinal implants. Mercia first invested in the company in 2017.
About Axis Spine Technologies
Axis Spine Technologies Ltd., a U.K. based startup with U.S. subsidiary, is first to market providing spine surgeons with a patient-optimized implant that is built intra-operatively to match patient anatomy and morphology. Its Axis-ALIF device is FDA 510(k) cleared and clinically introduced in selected spine centers in the United States. For more information, visit www.axisspinetech.com
For press enquiries please contact:
Jon Arcos, CEO & Founder email@example.com +44 (0) 7399 499579